Ben Greenblum specializes in complex civil litigation, with an emphasis on antitrust and intellectual property disputes. Ben litigates on behalf of corporations and individuals in federal and state courts across the country, and has served as lead defense counsel in several multidistrict litigation and other complex proceedings.
In 2014, Ben was part of the trial team that defended an international pharmaceutical company from a $60 billion antitrust claim alleging a so-called “reverse payment” patent settlement. The case was the first of its kind to go to trial, and to date the only of its kind to go to verdict. The jury’s verdict for the defense was affirmed on appeal. Since then, Ben has represented several pharmaceutical firms in various high stakes antitrust disputes.
Ben also has experience in a range of other substantive areas, including food and drug law, securities law, and claims of unfair competition, fraud and breach of contract. He has represented several companies in contract, licensing and antitrust disputes related to their intellectual property. He has also defended clients in Federal Trade Commission investigations.
Benchmark Litigation has included Ben in their rankings since 2019. He was also selected as a “Rising Star” in the 2014 through 2017 Washington, D.C. editions of Super Lawyers.
Updated Oct 2021